Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy

A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy

Radiation

No Radiation

Wendy Parulekar

Site Public Contact

Nicholas DiBella

Christopher M. Morrison

Aakash Batra

Samantha A. Seaward

Jason C. Ye

Charles W. Drescher

Robert B. Ash

Erin H. Healy

Amir Lavaf

Shahzad Siddique

Tyler Y. Kang

Janie G. Weng Grumley

Rachel A. Rabinovitch

Julie A. Weintraub

Supriya Jain

Christine Chin

Sonali Rudra

Jean L. Wright

Samuel M. Richter

Roberto Diaz

Cristiane Takita

Ignacio Castellon

Laura A. Vallow

Joseph E. Panoff

Iman R. Washington

Eva M. Suarez

John A. Pablo

John M. Schallenkamp

Eric D. Donnelly

Thomas Kim

Steven J. Chmura

Bryan A. Faller

Arpi Thukral

Poornima Saha

William Small

Arica Hirsch

Fahrettin Covut

Timothy Whelan

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Women with node positive breast cancer normally will receive endocrine therapy and some may receive chemotherapy to help prevent the cancer from coming back. Many women will also receive radiotherapy to the whole breast/chest area and the surrounding lymph glands (called regional radiotherapy). No one really knows whether patients with low risk breast cancer need to receive regional radiotherapy. Some women may be getting regional radiotherapy who do not need it. These women may be exposed to the side effects of their treatment without benefit.

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC.

Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC

Defined as the time from randomization to the time of death from any cause

Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast or regional nodes, or death to due to BC

Defined as time from randomization to time of invasive recurrent disease in distant sites or death due to BC

A Fisher's Exact Test will be used to compare lymphedema and arm abduction deficit between two arms. Defined as a difference in arm abduction of 10% or greater in the comparison of the ipsilateral to the contralateral arm.

using the NSABP Questionnaire for patients treated by BCS or mastectomy.

Overall QOL (EORTC QLQ-C30) will be compared between the two treatment groups using a similar approach.

Costs will be expressed in $US and $CAN base currencies based on the final year of the study. An average cost per study subject by treatment arm for an overall mean cost per study arm will be generated

breast symptoms (NSABP B32 Questionnaire) will be compared between the two treatment groups using a similar approach.

skin symptoms and fatigue (EORTC QLQ-BR23) will be compared between the two treatment groups using a similar approach.

Alliance for Clinical Trials in Oncology

Eastern Cooperative Oncology Group

NRG Oncology

SWOG Cancer Research Network

Canadian Cancer Trials Group

radiotherapy of 50Gy/25/f/5w to the ipsilateral chest wall and supraclavicular region

radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region

radiation

no radiation

Ye-xiong Li, M.D.

The purpose of this study is to evaluate postmastectomy radiotherapy in breast cancer patients with one to three positive nodes.

Eligible breast cancer patients with mastectomy and axillary dissection are randomized into 2 groups:radiotherapy of 50 Gy in 25 fractions within 5 weeks to ipsilateral chest wall and supraclavicular nodal region,and no radiotherapy.

During and after radiotherapy, the patients are followed and the efficacy and toxicities of radiotherapy are evaluated.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer	NCT03488693	Breast Cancer	Radiation No Radiation	35 Years -	Canadian Cancer Trials Group
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer	NCT03488693	Breast Cancer	Radiation No Radiation	35 Years -	Canadian Cancer Trials Group
Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes	NCT00805597	Breast Cancer	radiation no radiation	18 Years - 75 Years	ChineseAMS

Spots Global Cancer Trial Database for no radiation

Every month we try and update this database with for no radiation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.